Skip to main content
DLBDolby LaboratoriesSell5.7·$58.56
SellModerate Confidence
Investment thesis

A perfect four-quarter earnings beat run with an average surprise of nearly 15%, strong 18% margins, and a high Piotroski score underpin a high-quality franchise that currently trades roughly 25% below the analyst consensus target — offering a risk/reward of approximately 4.6-to-1 in the buyer's favor — but a death cross is in place, the stock is in a confirmed downtrend with RSI near oversold, and 93% licensing concentration adds structural risk; timing is the primary near-term obstacle to expressing this value.

Thesis pillars

  • High Quality Margins And Financials→Stable
  • Perfect Earnings Beat Streak↑Improving
  • Attractive Risk Reward Geometry↓Deteriorating
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Dolby Laboratories (DLB) Stock Analysis

Falling Knife setup

SellVALUE-TRAP 1/5GrowthModerate Confidence

Industrials · Specialty Business Services

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $58.56 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers.

Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to approximately 1,000 device manufacturers, generating 93% of fiscal 2025 revenue from licensing and 7% from cinema hardware and services. Per-unit royalties from... Read more

$58.56+14.7% A.UpsideScore 5.7/10#11 of 31 Specialty Business Services
QualityF-score8 / 9FCF yield6.15%
IncomeYield2.50%(5y avg 1.47%)Payout60.00%sustainable
Stop $54.76Target $67.15(analyst − 15%)A.R:R 2.3:1
Analyst target$79.00+34.9%3 analysts
$67.15our TP
$58.56price
$79.00mean
$90

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $58.56 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 5.7/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 53d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: moderate.

10-K grounded · weekly refresh

About Dolby Laboratories

About Dolby Laboratories

Dolby Laboratories derived 93% of fiscal 2025 revenue from licensing technology, brands, and patents to approximately 1,000 consumer electronics manufacturers globally. Broadcast markets (televisions and set-top boxes) represented 34% of licensing revenue in fiscal 2025, Mobile (smartphones and tablets) 22%, CE (Blu-ray, AVRs, soundbars) 12%, PC 12%, and Other markets including Dolby Cinema and Automotive 20%. The company held approximately 28,400 issued patents across more than 200 jurisdictions as of September 26, 2025, with 4,179 new patents issued in fiscal 2025.

Dolby earns licensing revenue through two channels: Branded Technology licensing (Dolby Atmos, Dolby Vision, DD+, and AC-4 codecs) sold to semiconductor manufacturers and OEMs under per-unit royalty, committed-volume, or fixed-fee arrangements, and Patent Licensing through pools administered by Access Advance, Sisvel, Via LA, and Vectis. Dolby holds majority ownership in Via LA alongside Philips and Mitsubishi. The licensing cycle typically runs in two stages — IC manufacturers embed Dolby technologies in chips, then OEM system manufacturers incorporate those chips and pay per-unit royalties. In fiscal 2025, Dolby shifted distribution of DD and DD+ codecs for Windows 11 24H2 PCs directly to PC OEMs, bypassing Microsoft's operating system channel. Products and services (7% of revenue) encompass cinema hardware including digital servers, audio processors, and amplifiers, plus Dolby Cinema box-office revenue-sharing. The company relies on sole source suppliers for certain components used in cinema hardware manufacturing.

Show full overview

Dolby's issued patents expire between 2025 and 2047, and licensing agreements generally require licensees to pay full royalties only while patents remain in force in relevant markets. If pool licensees determine that pooled patents lack sufficient aggregate value, they may not renew their agreements — a risk that applies across Access Advance, Sisvel, Via LA, and Vectis pools. With approximately 6,100 pending patent applications as of September 26, 2025, the company's revenue sustainability depends on continued successful patent prosecution and active participation in international standards bodies including ETSI, ISO, IEC, and ITU.

See also: Industrials · Specialty Business Services

From Dolby Laboratories's most recent 10-K filing, extracted June 9, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-26
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Tue, Nov 17, 202653d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
Risks
Concentration risk — Product: licensing (93.0%)
Concentration risk — Supplier: sole source suppliers
Sector modifier (Industrials): -0.7

Key Metrics

P/E (TTM)24.5
P/E (Fwd)12.6
Mkt Cap$5.4B
EV/EBITDA13.5
Profit Mgn16.7%
ROE8.8%
Rev Growth-3.3%
Beta0.80
Dividend2.50%
Rating analysts10

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.04bullish
IV53%elevated

Concentration Risks(10-K Item 1A)

  • HIGHProductlicensing93%
    10-K Item 1: 'We generated 93% of our revenues in fiscal 2025 by licensing technology, brand, and patents'
  • HIGHSuppliersole source suppliers
    10-K Item 1: 'we rely on sole source suppliers for certain components used to manufacture our products'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Volume
0.3
Ma Position
2.0
Rsi
3.5
Obv
6.0
Below 200-MA (recent, shallow — too early to call)
GatesMomentum 2.4<4.5Death cross (50MA < 200MA)A.R:R 2.3 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 53d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Moderate
RSI
38 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $56.39Resistance $65.70

Price Targets

$55
$67
A.Upside+14.7%
A.R:R2.3:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! momentum at 2.4 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
B
B
B
4/4 beats
Next Earnings2026-11-17 (53d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is DLB stock a buy right now?

Sell if holding. Momentum 2.4/10 is below the 5.0 floor at $58.56 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $54.76. Score 5.7/10, moderate confidence.

What is the DLB stock price target?

Take-profit target: $67.15 (+14.7% upside). Prior stop was $54.76. Stop-loss: $54.76.

What are the risks of investing in DLB?

Concentration risk — Product: licensing (93.0%); Concentration risk — Supplier: sole source suppliers; Sector modifier (Industrials): -0.7.

Is DLB overvalued or undervalued?

Dolby Laboratories trades at a P/E of 24.5 (forward 12.6). TrendMatrix value score: 6.1/10. Verdict: Sell.

What do analysts say about DLB?

10 analysts cover DLB with a consensus score of 4.1/5. Average price target: $79.

What does Dolby Laboratories do?Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to...

Dolby Laboratories licenses audio and video technologies — including Dolby Atmos, Dolby Vision, and audio codecs — to approximately 1,000 device manufacturers, generating 93% of fiscal 2025 revenue from licensing and 7% from cinema hardware and services. Per-unit royalties from OEMs across broadcast, mobile, PC, and CE device markets drive the licensing model. The company held approximately 28,400 issued patents as of September 26, 2025.

Related stocks: CASS (Cass Information Systems, Inc) · ULS (UL Solutions Inc.) · RBA (RB Global, Inc.) · KODK (Eastman Kodak Company) · CMPR (Cimpress PLC)
Home › Stocks › DLB

Latest news

Latest News

MarketBeat59d ago
StockStory59d agoEarnings
MarketBeat150d ago
StockStory150d agoEarnings
MarketBeat31d agoAnalyst
GuruFocus156d agoProduct
MarketBeat157d ago
Vinanet.vn37d ago
TipRanks38d agoLeadership Change
MarketBeat44d ago
MarketBeat80d ago
富途牛牛52d ago
MarketBeat60d ago
MarketBeat60d ago
TradingKey60d ago
AOL.ca31d agoProduct
MarketBeat67d ago
Dars.gov.et38d ago
Sahm39d agoProduct
MarketBeat39d ago
Loading more...